Những nghiên cứu mới về vắc-xin Covid-19 (Cập nhật từ ngày đến ngày 17/6/2022)

Cập nhật vào: Thứ sáu - 17/06/2022 12:00 Cỡ chữ Nhỏ Lớn

Vắc-xin cứu sống hàng triệu người mỗi năm. Việc phát triển vắc-xin COVID-19 an toàn và hiệu quả là một bước tiến lớn trong nỗ lực toàn cầu của chúng tôi nhằm chấm dứt đại dịch và để chúng ta quay trở lại làm nhiều việc có ích hơn nữa cùng với những người chúng ta yêu thương.

Để hiểu rõ hơn Cục Thông tin khoa học và công nghệ quốc gia xin giới thiệu một số bài nghiên cứu đã được xuất bản chính thức và các bài viết được chấp nhận đăng trên những cơ sở dữ liệu học thuật chính thống. Những nghiên cứu công bố trước đó trong năm 2022 được tổng hợp tại đường link cuối bài.

1. Sciendriect

1. Does mRNA SARS-CoV-2 vaccine detrimentally affect male fertility, as reflected by semen analysis?

Reproductive BioMedicine Online, 4 October 2021, Volume 44, Issue 1 (Cover date: January 2022), Pages 145-149

Dror Lifshitz, Jigal Haas, Adva Aizer

https://www.sciencedirect.com/science/article/pii/S1472648321004806/pdfft?md5=361e2ea8fa94157ee15afa81d51ac999&pid=1-s2.0-S1472648321004806-main.pdf

2. Vaccine-induced immune thrombotic thrombocytopenia

The Lancet Haematology, 11 November 2021, ,Volume 9, Issue 1 (Cover date: January 2022), Pages e73-e80

Frederikus A Klok, Menaka Pai, Michael Makris

https://www.sciencedirect.com/science/article/pii/S2352302621003069/pdfft?md5=ef885ffa77c61cbd750c848b09ab70c0&pid=1-s2.0-S2352302621003069-main.pdf

3. A vaccine built from potential immunogenic pieces derived from the SARS-CoV-2 spike glycoprotein: A computational approximation

Journal of Immunological Methods, 7 January 2022, Volume 502 (Cover date: March 2022), Article 113216

Jose Marchan

https://www.sciencedirect.com/science/article/pii/S0022175922000035/pdfft?md5=43924b0f8c04de6e4f8f9927af59fbd4&pid=1-s2.0-S0022175922000035-main.pdf

4. SARS-CoV-2 mRNA vaccine induces robust specific and cross-reactive IgG and unequal neutralizing antibodies in naive and previously infected people

Cell Reports, 20 January 2022, Volume 38, Issue 5 (Cover date: 1 February 2022), Article 110336

Tara M. Narowski, Kristin Raphel, Lakshmanane Premkumar

https://www.sciencedirect.com/science/article/pii/S2211124722000523/pdfft?md5=2f6863f8eb770850bfbafb802e54cf0d&pid=1-s2.0-S2211124722000523-main.pdf

5. SARS-CoV 2 spike protein S1 subunit as an ideal target for stable vaccines: A bioinformatic study

Materials Today: Proceedings, 15 July 2021, Volume 49, Part 3 (Cover date: 2022), Pages 904-912

Nagesha S.N., Ramesh B.N., Shreeram S. Chandaragi

https://www.sciencedirect.com/science/article/pii/S2214785321050227/pdfft?md5=468ba4b3a14e7346df8d766c5d5d8618&pid=1-s2.0-S2214785321050227-main.pdf

6. Comparative effectiveness of mRNA-1273 and BNT162b2 against symptomatic SARS-CoV-2 infection

Med, 11 December 2021, Volume 3, Issue 1 (Cover date: 14 January 2022), Pages 28-41.e8

Arjun Puranik, Patrick J. Lenehan, Venky Soundararajan

https://www.sciencedirect.com/science/article/pii/S2666634021003822/pdfft?md5=73525427889b943e8b7a65523ba414fe&pid=1-s2.0-S2666634021003822-main.pdf

7. Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination

Blood, 6 December 2021, Volume 139, Issue 5 (Cover date: 3 February 2022), Pages 678-685

Yair Herishanu, Galia Rahav, Ohad Benjamini

https://www.sciencedirect.com/science/article/pii/S0006497121019959/pdfft?md5=c72b059833841849864da38a577abfef&pid=1-s2.0-S0006497121019959-main.pdf

8. Acriflavine, a clinically approved drug, inhibits SARS-CoV-2 and other betacoronaviruses

Cell Chemical Biology, Available online 11 January 2022, In press, corrected proof

Valeria Napolitano, Agnieszka Dabrowska, Krzysztof Pyrc

https://www.sciencedirect.com/science/article/pii/S2451945621005134/pdfft?md5=410e7e56a0e4f461b7b5ec8293282430&pid=1-s2.0-S2451945621005134-main.pdf

9. Phase I interim results of a phase I/II study of the IgG-Fc fusion COVID-19 subunit vaccine, AKS-452

Vaccine, Available online 31 January 2022 In press, corrected proof

Yester F. Janssen, Eline A. Feitsma, Todd C. Zion

https://www.sciencedirect.com/science/article/pii/S0264410X22000779/pdfft?md5=b5d354c20776a8eedae8a7b0fb25ad8c&pid=1-s2.0-S0264410X22000779-main.pdf

10. Sensitivity theorems of a model of multiple imperfect vaccines for COVID-19.

Chaos, Solitons & Fractals, 31 January 2022, Volume 156 (Cover date: March 2022), Article 111844

Fernando Javier Aguilar-Canto, Ugo Avila-Ponce de León, Eric Avila-Vales

https://www.sciencedirect.com/science/article/pii/S0960077922000558/pdfft?md5=d147a994dc8e9fb4bee3cd0069f0875b&pid=1-s2.0-S0960077922000558-main.pdf

11. Safety and immunogenicity of the measles vector-based SARS-CoV-2 vaccine candidate, V591, in adults: results from a phase 1/2 randomised, double-blind, placebo-controlled, dose-ranging trial

eBioMedicine, 15 January 2022, Volume 75 (Cover date: January 2022), Article 103811

Frédéric Vanhoutte, Wen Liu, Eseng Lai

https://www.sciencedirect.com/science/article/pii/S2352396421006058/pdfft?md5=747175477b37ba358ad108712055e0c8&pid=1-s2.0-S2352396421006058-main.pdf

12. Three waves changes, new variant strains, and vaccination effect against COVID-19 pandemic

International Journal of Biological Macromolecules, 22 January 2022, Volume 204 (Cover date: 15 April 2022), Pages 161-168

Rehan M. El-Shabasy, Mohamed A. Nayel, El Refaie Kenawy

https://www.sciencedirect.com/science/article/pii/S0141813022001349/pdfft?md5=decb7b5886b99c63fd396837dd37483e&pid=1-s2.0-S0141813022001349-main.pdf

13. COVID-19 vaccine and pregnancy: A Safety weapon against pandemic

Taiwanese Journal of Obstetrics and Gynecology, Available online 10 February 2022 In press, journal pre-proof

Navneet Magon, Shail Prasad, Jai Bhagwan Sharma

https://www.sciencedirect.com/science/article/pii/S1028455922000055/pdfft?md5=0985d3d7c3680a35b0d843160a4071ff&pid=1-s2.0-S1028455922000055-main.pdf

14. Serological reactivity of inactivated SARS-CoV-2 vaccine based on an S-RBD neutralizing antibody assay

International Journal of Infectious Diseases, Available online 1 February 2022 In press, journal pre-proof

Hui Zhang, Xingtian Liu, Shuping Zhao

https://www.sciencedirect.com/science/article/pii/S1201971222000698/pdfft?md5=898688119e7574015742c0c8d154364b&pid=1-s2.0-S1201971222000698-main.pdf

15. Humoral response to the SARS-CoV-2 BNT162b2 mRNA vaccine: Real-world data from a large cohort of healthcare workers

Vaccine, 11 December 2021, Volume 40, Issue 4 (Cover date: 28 January 2022), Pages 650-655

Joana Oliveira-Silva, Teresa Reis, Isabel Antunes

https://www.sciencedirect.com/science/article/pii/S0264410X21016212/pdfft?md5=ba914caac1f697c546b7ca73bc103ed9&pid=1-s2.0-S0264410X21016212-main.pdf

16. Innovations and development of Covid-19 vaccines: A patent review

Journal of Infection and Public Health, 23 October 2021, Volume 15, Issue 1 (Cover date: January 2022), Pages 123-131

Ahmed S. Alshrari, Shuaibu A. Hudu, Syed Imam Rabbani

https://www.sciencedirect.com/science/article/pii/S1876034121003427/pdfft?md5=d77887474e18d168bf2651548e59cd2b&pid=1-s2.0-S1876034121003427-main.pdf

17. The BNT162b2 mRNA Covid-19 vaccine does not impair sperm parameters

Reproductive BioMedicine Online, Available online 31 January 2022 In press, journal pre-proof

Myriam Safrai, Shmuel Hertzberg, Assaf Ben-Meir

https://www.sciencedirect.com/science/article/pii/S1472648322000414/pdfft?md5=b7c6b62518a6ef5f259dbf47809e86ee&pid=1-s2.0-S1472648322000414-main.pdf

18. A single mRNA vaccine dose in COVID-19 patients boosts neutralizing antibodies against SARS-CoV-2 and variants of concern

Cell Reports Medicine, 14 December 2021, Volume 3, Issue 1 (Cover date: 18 January 2022), Article 100486

Marit J. van Gils, Hugo D. G. van Willigen, Menno D. de Jong

https://www.sciencedirect.com/science/article/pii/S266637912100358X/pdfft?md5=5a8b50bb790634101acfef46c78ab41f&pid=1-s2.0-S266637912100358X-main.pdf

19. Antibacterial and antiviral high-performance nanosystems to mitigate new SARS-CoV-2 variants of concern

Current Opinion in Biomedical Engineering, 1 December 2021, Volume 21 (Cover date: March 2022), Article 100363

Shivani Tiwari, Subhavna Juneja, Ajeet Kaushik

https://www.sciencedirect.com/science/article/pii/S2468451121001033/pdfft?md5=f2b0a9ecb01e6c713c0ecfc328569352&pid=1-s2.0-S2468451121001033-main.pdf

20. Third dose of anti-SARS-CoV-2 vaccine for patients with cancer: Should humoral responses be monitored? A position article

European Journal of Cancer, 16 December 2021, Volume 162 (Cover date: February 2022), Pages 182-193

Jérôme Barrière, Michel Carles, Gérard Zalcman

https://www.sciencedirect.com/science/article/pii/S0959804921012752/pdfft?md5=5eea6584f24f8ce77bb6a9a0e8c034e1&pid=1-s2.0-S0959804921012752-main.pdf

21. Designing AbhiSCoVac - A single potential vaccine for all ‘corona culprits’: Immunoinformatics and immune simulation approaches

Journal of Molecular Liquids, 31 January 2022, Volume 351 (Cover date: 1 April 2022), Article 118633

Abhigyan Choudhury, Parth Sarthi Sen Gupta, Suprabhat Mukherjee

https://www.sciencedirect.com/science/article/pii/S0167732222001702/pdfft?md5=29fab9e7108e1d894292cea31405771d&pid=1-s2.0-S0167732222001702-main.pdf

22. Computational construction of a glycoprotein multi-epitope subunit vaccine candidate for old and new South-African SARS-CoV-2 virus strains

Informatics in Medicine Unlocked, 15 January 2022, Volume 28 (Cover date: 2022), Article 100845

Olugbenga Oluseun Oluwagbemi, Elijah Kolawole Oladipo, Adewale Joseph Ogunleye

https://www.sciencedirect.com/science/article/pii/S2352914822000028/pdfft?md5=ed0cd1ba6ec9a6c49f5c9ffd65b501b1&pid=1-s2.0-S2352914822000028-main.pdf

23. Comparative analyses of IgG/IgA neutralizing effects induced by three COVID-19 vaccines against variants of concern

Journal of Allergy and Clinical Immunology, Available online 29 January 2022 In press, journal pre-proof

Eliott Lafon, Michael Jäger, Wilfried Posch

https://www.sciencedirect.com/science/article/pii/S0091674922000835/pdfft?md5=2d7a83a48427309a34d35a1a4563caeb&pid=1-s2.0-S0091674922000835-main.pdf

24. Modulation of immunosuppressant drug treatment to improve SARS-CoV-2 vaccine efficacy in mice

Vaccine, 31 December 2021, Volume 40, Issue 6 (Cover date: 7 February 2022), Pages 854-861

Amy V. Paschall, Ahmet Ozdilek, Fikri Y. Avci

https://www.sciencedirect.com/science/article/pii/S0264410X21016662/pdfft?md5=a42700b233422c55e565c19f1cb164dc&pid=1-s2.0-S0264410X21016662-main.pdf

25. Intranasal COVID-19 vaccines: From bench to bed

eBioMedicine, 24 January 2022, Volume 76 (Cover date: February 2022), Article 103841

Aqu Alu, Li Chen, Xiawei Wei

https://www.sciencedirect.com/science/article/pii/S2352396422000251/pdfft?md5=c54f603801c5604e4ea2651668ad90ab&pid=1-s2.0-S2352396422000251-main.pdf

2. Springer

1. A review of the safety and efficacy of current COVID-19 vaccines

Zehong Huang, Yingying Su, Tianying Zhang, Ningshao Xia in Frontiers of Medicine (2022)

https://link.springer.com/content/pdf/10.1007%2Fs11684-021-0893-y.pdf

2. Sentiment analysis and topic modeling for COVID-19 vaccine discussions

Hui Yin, Xiangyu Song, Shuiqiao Yang, Jianxin Li in World Wide Web (2022)

https://link.springer.com/content/pdf/10.1007%2Fs11280-022-01029-y.pdf

3. SARS-CoV-2 vaccine research and immunization strategies for improved control of the COVID-19 pandemic

Yiming Shao, Yingqi Wu, Yi Feng, Wenxin Xu, Feng Xiong… in Frontiers of Medicine (2022)

https://link.springer.com/content/pdf/10.1007%2Fs11684-021-0913-y.pdf

4. Vaccination With Routine Childhood Vaccines and Severity of COVID-19 Among Children in Delhi

Dr Madan Mohan Majhi, Amod Laxmikant Borle, Panna Lal, Meenu Meena… in Indian Pediatrics (2022)

https://link.springer.com/content/pdf/10.1007%2Fs13312-022-2445-1.pdf

5. AstraZeneca ChAdOx1-S COVID-19 vaccine can be safely administered in patients with EDTA allergy

Syed B. Ali, Griffith Perkins, Dongjae Ryoo… in Allergy, Asthma & Clinical Immunology (2022)

https://link.springer.com/content/pdf/10.1186%2Fs13223-022-00665-3.pdf

6. COVID-19 vaccine perceptions in the initial phases of US vaccine roll-out: an observational study on reddit

Navin Kumar, Isabel Corpus, Meher Hans, Nikhil Harle, Nan Yang… in BMC Public Health (2022)

https://link.springer.com/content/pdf/10.1186%2Fs12889-022-12824-7.pdf

3. Pubmed

1. Association between social media use and the acceptance of COVID-19 vaccination among the general population in Saudi Arabia - a cross-sectional study.

Othman SS, Alsuwaidi A, Aseel R, Alotaibi R, Bablgoom R, Alsulami G, Alharbi R, Ghamri R.

BMC Public Health. 2022 Feb 21;22(1):375. doi: 10.1186/s12889-022-12757-1.

PMID: 35189874

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8860460/pdf/12889_2022_Article_12757.pdf

2. Psychological, social, and situational factors associated with COVID-19 vaccination intentions: A study of UK key workers and non-key workers.

Butter S, McGlinchey E, Berry E, Armour C.

Br J Health Psychol. 2022 Feb;27(1):13-29. doi: 10.1111/bjhp.12530. Epub 2021 May 5.

PMID: 33949038

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8236922/pdf/BJHP-9999-.pdf

3. Does smoking have an impact on the immunological response to COVID-19 vaccines? Evidence from the VASCO study and need for further studies.

Ferrara P, Ponticelli D, Agüero F, Caci G, Vitale A, Borrelli M, Schiavone B, Antonazzo IC, Mantovani LG, Tomaselli V, Polosa R.

Public Health. 2022 Feb;203:97-99. doi: 10.1016/j.puhe.2021.12.013.

PMID: 35038631

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8786634/pdf/main.pdf

4. Fourth dose of COVID-19 vaccines in Israel.

Burki TK.

Lancet Respir Med. 2022 Feb;10(2):e19. doi: 10.1016/S2213-2600(22)00010-8. Epub 2022 Jan 11.

PMID: 35030317

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8752098/pdf/main.pdf

5. Heterologous vaccination interventions to reduce pandemic morbidity and mortality: Modeling the US winter 2020 COVID-19 wave.

Hupert N, Marín-Hernández D, Gao B, Águas R, Nixon DF.

Proc Natl Acad Sci U S A. 2022 Jan 18;119(3):e2025448119. doi: 10.1073/pnas.2025448119.

PMID: 35012976

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8784160/pdf/pnas.202025448.pdf

6. "Covid arm": Abnormal side effect after Moderna COVID-19 vaccine.

Picone V, Martora F, Fabbrocini G, Marano L.

Dermatol Ther. 2022 Jan;35(1):e15197. doi: 10.1111/dth.15197. Epub 2021 Nov 16.

PMID: 34750923

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8646724/pdf/DTH-9999-e15197.pdf

7. Should the world collaborate imminently to develop neglected live-attenuated vaccines for COVID-19?

Chen JM.

J Med Virol. 2022 Jan;94(1):82-87. doi: 10.1002/jmv.27335. Epub 2021 Sep 21.

PMID: 34524688

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8662152/pdf/JMV-94-82.pdf

8. Who is likely to vacillate in their COVID-19 vaccination decision? Free-riding intention and post-positive reluctance.

Caserotti M, Gavaruzzi T, Girardi P, Tasso A, Buizza C, Candini V, Zarbo C, Chiarotti F, Brescianini S, Calamandrei G, Starace F, de Girolamo G, Lotto L.

Prev Med. 2022 Jan;154:106885. doi: 10.1016/j.ypmed.2021.106885. Epub 2021 Nov 12.

PMID: 34774880

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8585567/pdf/main.pdf

9. Changes in infectivity, severity and vaccine effectiveness against delta COVID-19 variant ten months into the vaccination program: The Israeli case.

Saban M, Myers V, Wilf-Miron R.

Prev Med. 2022 Jan;154:106890. doi: 10.1016/j.ypmed.2021.106890. Epub 2021 Nov 17.

PMID: 34800471

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8596646/pdf/main.pdf

10. Neurological autoimmune diseases following vaccinations against SARS-CoV-2: a case series.

Kaulen LD, Doubrovinskaia S, Mooshage C, Jordan B, Purrucker J, Haubner C, Seliger C, Lorenz HM, Nagel S, Wildemann B, Bendszus M, Wick W, Schönenberger S.

Eur J Neurol. 2022 Feb;29(2):555-563. doi: 10.1111/ene.15147. Epub 2021 Oct 31.

PMID: 34668274

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8652629/pdf/ENE-9999-0.pdf

Các công bố về COVID-19 trước thời gian trên:

Cập nhật các công bố về COVID-19 từ ngày 4/6 đến ngày 10/6/2022

https://vista.gov.vn/news/khoa-hoc-y-duoc/trieu-chung-viem-phoi-do-virut-corona-cap-nhat-den-ngay-10-6-2022-5111.html

Cập nhật các công bố về COVID-19 từ ngày 28/5 đến ngày 03/6/2022

https://vista.gov.vn/news/khoa-hoc-y-duoc/tac-dong-cua-covid-19-den-giao-duc-cap-nhat-den-ngay-03-6-2022-5079.html

Cập nhật các công bố về COVID-19 từ ngày 21/5 đến ngày 27/5/2022

https://vista.gov.vn/news/khoa-hoc-y-duoc/sars-cov-2-virut-gay-benh-covid-19-cap-nhat-tu-ngay-21-5-den-ngay-27-5-2022-5078.html

Cập nhật các công bố về COVID-19 từ ngày 07/5 đến ngày 13/5/2022

https://vista.gov.vn/news/khoa-hoc-y-duoc/covid-19-o-tre-em-cap-nhat-den-ngay-13-5-2022-4982.html